| NCT ID | NCT05204459 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cedars-Sinai Medical Center |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-11-11 |
| Primary Completion | 2041-11-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2021-11-11 with a primary completion date of 2041-11-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and/or spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.
Eligibility Criteria
Inclusion Criteria: * Subjects who meet any one of the following diagnostic criteria: * Diagnosis of MS, CIS,or RIS based on the 2017 revised McDonald criteria. * Diagnosis of NMOSD based on the 2015 revised NMOSD consensus diagnostic criteria. * Diagnosis of myelin oligodendrocyte glycoprotein (MOG)-related encephalomyelitis, optic neuritis, or other associated disease. * Diagnosis of neurological disorders other than MSRD. * Healthy volunteer. * Age ≥18. * Able to give informed consent. Exclusion Criteria: * Patients will be excluded from the MRI portions of the study if they have a contraindication to MRI(metallic implantsor foreign bodies, claustrophobia, MRI-incompatible pacemakers, MRI- incompatible prosthetic heart valves). * Patients will be excluded from the MRI portions of the study if they are pregnant, but their demographic, clinical information,and disability measures may still be captured under the study. * Patients will be excluded from the visual assessment portions of the study if they have had any recent ocular surgery (within the past two months), refractive errors of greater than or equal to ±6 diopters or other eye diseases that may affect or confound OCT/OCTA measurements (ex., age-related macular degeneration, advanced geographic atrophy, diabetic retinopathy, glaucoma).
Contact & Investigator
Omar Al-Louzi, MD
PRINCIPAL INVESTIGATOR
Cedars-Sinai Medical Center
Frequently Asked Questions
Who can join the NCT05204459 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05204459 currently recruiting?
Yes, NCT05204459 is actively recruiting participants. Contact the research team at omar.allouzi@cshs.org for enrollment information.
Where is the NCT05204459 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT05204459 clinical trial?
NCT05204459 is sponsored by Cedars-Sinai Medical Center. The principal investigator is Omar Al-Louzi, MD at Cedars-Sinai Medical Center. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.